| Clinical Trial Stage Projects | University of California, San Diego | A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
| Late Stage Preclinical Projects | University of California, San Diego | Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies |
$2,160,000 |
| Disease Team Therapy Development III | University of California, San Diego | Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) |
$4,179,598 |
